Deviation – Page 143

Complaint Handling Deficiency during FDA inspection: CAPA plan with effectiveness checks

Addressing Complaint Handling Deficiencies during FDA Inspections: Formulating a CAPA Plan with Effectiveness Checks Pharmaceutical manufacturers often face challenges during inspections, particularly regarding complaint handling processes. Inefficient or ineffective systems…

Risk Management File Gap during lifecycle management: batch release impact and documentation pack

Addressing Gaps in Risk Management Files During Lifecycle Management: Implications for Batch Release and Documentation In the highly regulated pharmaceutical industry, the integrity of a product lifecycle management process is…

Software Validation Gap for drug-device combination products: ownership between drug GMP and device QMS

Addressing Software Validation Gaps in Drug-Device Combination Products In today’s pharmaceutical landscape, drug-device combination products pose unique challenges in maintaining compliance with Good Manufacturing Practice (GMP) standards and ensuring safety…

API starting material traceability gap after milling / micronization change: data integrity and chromatographic audit trail review steps

Investigating API Starting Material Traceability Gaps After Milling or Micronization Changes In the world of pharmaceutical manufacturing, maintaining the integrity of API starting materials is crucial. Occasional deviations can lead…

Cryopreservation failure during ATMP manufacturing: inspection-ready investigation package

Investigation Package for Cryopreservation Failures in ATMP Manufacturing Cryopreservation is a critical process in the manufacturing of Advanced Therapy Medicinal Products (ATMPs), ensuring the viability of cellular and tissue-based therapies.…

Pump Actuation Failure in nasal spray filling: how to trend dose delivery data in CPV

Pump Actuation Failure in Nasal Spray Filling: Strategies for Trending Dose Delivery Data in Continuous Process Verification Pump actuation failure during nasal spray filling can lead to significant quality issues,…

Dhf Missing during FDA inspection: batch release impact and documentation pack

Impact of Missing DHF during FDA Inspections on Batch Release Documentation In the highly regulated environment of pharmaceutical manufacturing, adherence to Good Manufacturing Practices (GMP) is crucial. One recurring issue…

Oos Investigation during tech transfer: ownership between drug GMP and device QMS

Managing OOS Investigations During Tech Transfer: Bridging Drug GMP and Device QMS In the intricate world of pharmaceutical manufacturing and device integration, deviations and out-of-specification (OOS) results can pose significant…

API stability failure at accelerated conditions during FDA inspection readiness: supplier qualification gaps and incoming testing upgrades to close the loop

Addressing API Stability Failures during FDA Inspection Readiness with Supplier Qualification and Testing Enhancements In the pharmaceutical manufacturing landscape, ensuring the stability of Active Pharmaceutical Ingredients (APIs) is critical for…

Vector potency drift during ATMP manufacturing: inspection-ready investigation package

Investigating Vector Potency Drift in ATMP Manufacturing: A Practical Guide Vector potency drift during Advanced Therapy Medicinal Product (ATMP) manufacturing poses significant risks to product consistency, safety, and regulatory compliance.…

Apsd Oos in DPI manufacturing: device qualification and assembly controls

Addressing Apsd Oos in DPI Manufacturing: Device Qualification and Assembly Controls In the domain of pharmaceutical manufacturing, especially in the production of dry powder inhalers (DPIs), Out of Specification (OOS)…

Gmp Gap for drug-device combination products: risk assessment and change control template

Identifying and Addressing GMP Gaps in Drug-Device Combination Products In the realm of pharmaceutical manufacturing, specifically concerning drug-device combination products, the compliance with Good Manufacturing Practices (GMP) is crucial. However,…